Psu2 Cta vs. Dsa for Post-Clipping Aneurysm Obliteration Detection: A Meta-Analysis

Abstract

Objectives: To evaluate the healthcare resource use and costs of patients initiating incrementally higher numbers of topical glaucoma medications (TGMs) for management of open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: This was a retrospective analysis of administrative claims data (Jan 2011 -July 2017) from the IQVIA PharMetrics Plus database. The study included patients $40 years with a diagnosis of OAG/OHT who underwent treatment initiation or intensification with $1 TGM of a different drug class during Jan 2012 -July 2015 (index period). Over a 2-year period, we evaluated the total health care costs including eyerelated physician care, glaucoma surgical costs, lab testing and pharmaceutical use. Results: In total, 48,402 patients (mean [SD] age 61.4 [9.6] years); underwent treatment intensification during the index period; of these, 22,874 (47.3%), 16,214 (33.5%), 7,137 (14.7%) and 2,177 (4.5%) received a one, two, three or four TGM classes, respectively, as their first observed intensified regimen ('index drop combination'). Among the index cohorts receiving 1, 2, 3 or 4 TGMs utilization and intensity of glaucoma service use increased monotonically with each additional drop with average non-inpatient costs (physician, labs and surgery